Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy SpringWorks Therapeutics stock | $61.12

Learn how to easily invest in SpringWorks Therapeutics stock.

SpringWorks Therapeutics Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 110 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in SpringWorks Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SWTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

SpringWorks Therapeutics stock price (NASDAQ: SWTX)

Use our graph to track the performance of SWTX stocks over time.

SpringWorks Therapeutics shares at a glance

Information last updated 2021-10-09.
Latest market close$61.12
52-week range$51.57 - $96.48
50-day moving average $69.50
200-day moving average $75.33
Wall St. target price$114.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.87

Buy SpringWorks Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy SpringWorks Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SpringWorks Therapeutics price performance over time

Historical closes compared with the close of $61.12 from 2021-10-15

1 week (2021-10-08) 11.55%
1 month (2021-09-17) -18.29%
3 months (2021-07-17) -25.60%
6 months (2021-04-16) -12.70%
1 year (2020-10-16) 3.37%
2 years (2019-10-17) 210.25%
3 years (2018-10-13) N/A
5 years (2016-10-13) N/A

SpringWorks Therapeutics financials

Revenue TTM $35 million
Gross profit TTM $35 million
Return on assets TTM -13.26%
Return on equity TTM -22.14%
Profit margin -249.1%
Book value $10.24
Market capitalisation $2.7 billion

TTM: trailing 12 months

Shorting SpringWorks Therapeutics shares

There are currently 3.1 million SpringWorks Therapeutics shares held short by investors – that's known as SpringWorks Therapeutics's "short interest". This figure is 4.2% down from 3.3 million last month.

There are a few different ways that this level of interest in shorting SpringWorks Therapeutics shares can be evaluated.

SpringWorks Therapeutics's "short interest ratio" (SIR)

SpringWorks Therapeutics's "short interest ratio" (SIR) is the quantity of SpringWorks Therapeutics shares currently shorted divided by the average quantity of SpringWorks Therapeutics shares traded daily (recently around 230525.47864507). SpringWorks Therapeutics's SIR currently stands at 13.58. In other words for every 100,000 SpringWorks Therapeutics shares traded daily on the market, roughly 13580 shares are currently held short.

However SpringWorks Therapeutics's short interest can also be evaluated against the total number of SpringWorks Therapeutics shares, or, against the total number of tradable SpringWorks Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SpringWorks Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 SpringWorks Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1173% of the tradable shares (for every 100,000 tradable SpringWorks Therapeutics shares, roughly 117 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against SpringWorks Therapeutics.

Find out more about how you can short SpringWorks Therapeutics stock.

SpringWorks Therapeutics share dividends

We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.

SpringWorks Therapeutics share price volatility

Over the last 12 months, SpringWorks Therapeutics's shares have ranged in value from as little as $51.57 up to $96.48. A popular way to gauge a stock's volatility is its "beta".

SWTX.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SpringWorks Therapeutics's is 0.8246. This would suggest that SpringWorks Therapeutics's shares are less volatile than average (for this exchange).

SpringWorks Therapeutics overview

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd. , GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.

Frequently asked questions

What percentage of SpringWorks Therapeutics is owned by insiders or institutions?
Currently 13.533% of SpringWorks Therapeutics shares are held by insiders and 91.827% by institutions.
How many people work for SpringWorks Therapeutics?
Latest data suggests 110 work at SpringWorks Therapeutics.
When does the fiscal year end for SpringWorks Therapeutics?
SpringWorks Therapeutics's fiscal year ends in December.
Where is SpringWorks Therapeutics based?
SpringWorks Therapeutics's address is: 100 Washington Boulevard, Stamford, CT, United States, 06902
What is SpringWorks Therapeutics's ISIN number?
SpringWorks Therapeutics's international securities identification number is: US85205L1070
What is SpringWorks Therapeutics's CUSIP number?
SpringWorks Therapeutics's Committee on Uniform Securities Identification Procedures number is: 844909101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site